Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Bioorg Med Chem. 2018 Apr 6;26(9):2514–2529. doi: 10.1016/j.bmc.2018.04.016

Fig. 10.

Fig. 10

iCa2+ concentration–response of the PAR1 agonist TFLLRN-NH2 in the presence of increasing concentrations of (A) vorapaxar, (B) RWJ 58259, (C) ML161, (D) RR-90.